December 12, 2007Open Access

Clinical Experience with α-Particle–Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

This study provides proof of concept for regional targeted radiotherapy with (211)At-labeled molecules in oncology. Specifically, the regional administration of (211)At-ch81C6 is feasible, safe, and associated with a promising antitumor benefit in patients with malignant central nervous system tumors.

Me gusta

Guardar

Ver artículo completo

Cite This Study

Zalutsky et al. (Wed,) studied this question.

synapsesocial.com/papers/69e2fd13029746a715d37c4e https://doi.org/https://doi.org/10.2967/jnumed.107.046938

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.2006 · 51 citations
2Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a phase I study.1999 · 82 citations
3Supratentorial malignant glioma: Patterns of recurrence and implications for external beam local treatment1992 · 295 citations
4Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies.1989 · 152 citations
5A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy1987 · 110 citations

Me gusta

Guardar

Ver artículo completo